glp 1 agonists and inflammation Frontiers Cardiovascular Effects of Glucagon-Like Peptide-1
Description
10.1074/jbc.M500540200
In the T2D group that received ghrelin, these decreases were far more pronounced
is on the speakers bureaus of and has served as a consultant for, received honoraria as a promotional speaker from, or participated in advisory boards for Abbott Laboratories, AstraZeneca, Bayer Laboratories, Boehringer Ingelheim, Lilly, Janssen Pharmaceuticals, Mylan Pharmaceuticals, and Novo Nordisk
[DOI] [PMC free article] [PubMed] [Google Scholar] 118.Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D
doi: 10.1016/j.jamda.2015.10.009
